M. Fontaine

Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study.

M. Shah, E. Van Cutsem, J. Tabernero, 2022, Clinical colorectal cancer.

The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.

M. Shah, Y. Bang, F. Lordick, 2018 .

O-7 FOLFIRI ± napabucasin in patients with previously treated metastatic colorectal cancer: Overall survival results from the phase 3 CanStem303C study

M. Shah, J. Tabernero, M. Fakih, 2021, Annals of Oncology.